VNDA
Vanda Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.12
+0.20%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.72
- Revenue estimate
- $69.3M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$1.04
- EPS estimate
- -$0.58
- Revenue actual
- $50.5M
- Revenue estimate
- $61.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -41.4%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $16
- PT range
- $12 – $20
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.58 | -$1.04 | Miss -78.54% | $50.5M |
| May 6, 2026 | -$0.53 | -$0.82 | Miss -54.72% | $51.7M |
| Feb 11, 2026 | -$2.18 | -$2.39 | Miss -9.63% | $57.2M |
| Oct 29, 2025 | -$0.31 | -$0.38 | Miss -22.58% | $56.3M |
| Jul 31, 2025 | -$0.34 | -$0.46 | Miss -35.29% | $52.6M |
| May 7, 2025 | -$0.55 | -$0.50 | Beat 9.09% | $50.0M |
| Feb 13, 2025 | -$0.14 | -$0.08 | Beat 42.86% | $53.2M |
| Jul 31, 2024 | -$0.21 | -$0.08 | Beat 61.90% | $50.5M |
| Feb 7, 2024 | -$0.09 | -$0.04 | Beat 55.56% | $45.3M |
| Nov 8, 2023 | $0.00 | $0.00 | Beat 100.00% | $38.8M |
| Jul 27, 2023 | -$0.13 | $0.03 | Beat 123.08% | $46.1M |
| May 3, 2023 | — | $0.06 | — | $62.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026